Epratuzumab (planned trade name LymphoCide) is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory...
5 KB (377 words) - 23:53, 14 June 2023
omega (INN) Epogen epoprostenol (INN) epostane (INN) eprazinone (INN) epratuzumab (INN) eprinomectin (INN) epristeride (INN) eprobemide (INN) eprodisate...
10 KB (466 words) - 17:42, 15 November 2024
Cedelizumab Certolizumab pegol Crizanlizumab Daclizumab Eculizumab Efalizumab‡ Epratuzumab Erlizumab Etrolizumab† Fontolizumab Frexalimab† Inebilizumab Itolizumab...
38 KB (4,316 words) - 10:24, 26 August 2024
announced the closing of the former Immunomedics facility in Morris Plains. Epratuzumab is a humanized anti-CD22 monoclonal antibody in phase III trials for...
5 KB (401 words) - 02:08, 20 September 2024
such as rituximab, obinutuzumab, galiximab, inotuzumab ozogamicin, or epratuzumab and immunomodulators such as lenalidomide and interferon. The latter...
67 KB (7,967 words) - 13:33, 14 October 2024
most promising seemed to be the anti-CD20 rituximab and the anti-CD22 epratuzumab, while the anti-TNF-α and IFN-α seemed less effective. In 2014, the Sjögren's...
87 KB (9,219 words) - 01:04, 14 November 2024
the extent of trogocytosis might improve their therapeutic efficacy. Epratuzumab (a CD22 Mab) acts using trogocytosis to transfer CD22 and other B-cell...
19 KB (2,135 words) - 16:27, 27 October 2024
diffuse large B-cell lymphoma Epitumomab cituxetan mab mouse episialin Epratuzumab mab humanized CD22 cancer, systemic lupus erythematosus (SLE) Eptinezumab...
137 KB (4,083 words) - 21:25, 19 October 2024
epoetin alfa – epoetin beta – epothilone – epothilone B – epothilone D – epratuzumab – Epstein-Barr virus – EPT – ER – ER+ – ER- – ERA-923 – erb-38 immunotoxin...
69 KB (5,119 words) - 11:20, 3 June 2024
expression is lost upon maturation to plasma cells. Epratuzumab (Lymphocide). After binding epratuzumab, CD22 is rapidly internalized. Cell death does not...
20 KB (2,453 words) - 10:36, 1 June 2024
Cedelizumab Certolizumab pegol Crizanlizumab Daclizumab Eculizumab Efalizumab‡ Epratuzumab Erlizumab Etrolizumab† Fontolizumab Frexalimab† Inebilizumab Itolizumab...
2 KB (87 words) - 01:28, 30 May 2023